TNGX News and Press, Tango Therapeutics Inc. From 11/08/23

2023-11-08 08:44:56 ET Tango Therapeutics press release ( NASDAQ: TNGX ): Q3 GAAP EPS of -$0.23. Revenue of $10.7M. For further details see: Tango Therapeutics GAAP EPS of -$0.23, revenue of $10.7M

– Dose escalation ongoing in phase 1/2 trials of lead PRMT5 inhibitors TNG908 and TNG462; additional TNG908 clinical data expected 2024 – – Dose escalation ongoing in phase 1/2 trial of CoREST inhibitor TNG260 and pembrolizumab in patients with STK11 mutant solid tu...

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics , Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer...

2023-10-23 18:26:00 ET Summary We are circling back on clinical stage developmental concern Tango Therapeutics, Inc. for the first time since November 2022. The company recently raised capital to fund all operations well into 2027, and a beneficial owner/director just added just o...

2023-10-13 11:20:21 ET More on Tango Therapeutics Tango Stock Surges On Peer Data Merits Excitement And Perspective Tango Therapeutics: Partial Phase 1 Data Has Not Helped Seeking Alpha’s Quant Rating on Tango Therapeutics Historical earnings data for ...

2023-10-13 10:00:01 ET More on Health Care Select Sector SPDR Stocks to watch in the Health Care sector as earnings close in BofA reports 10th consecutive week of equity inflows Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR For further...

2023-10-12 15:09:10 ET More on Tango Therapeutics Tango Therapeutics: Partial Phase 1 Data Has Not Helped Seeking Alpha’s Quant Rating on Tango Therapeutics Historical earnings data for Tango Therapeutics For further details see: Tango Therapeutics...

2023-10-09 13:10:55 ET More on Bristol-Myers Squibb Company , Mirati Therapeutics Bristol-Myers' Mirati Takeover: Pharma Is Either Buying Crown Jewels Or A Dud Bristol-Myers: Out Of Favor (Rating Upgrade) Bristol-Myers Squibb: How Cheap Is Cheap Enough? ...

2023-10-09 11:53:07 ET Shares of Tango Therapeutics (NASDAQ: TNGX) were down more than 12% as of 11:15 a.m. on Monday. The healthcare stock is up more than 37% this year. Tango is a clinical-stage biotech that focuses on precision oncology therapies. The stock reached a ...

2023-10-09 10:00:00 ET More on Health Care Select Sector SPDR Citi turns cautious on pharmaceuticals and biotech BofA Securities: Which small cap non-earner stocks to avoid For further details see: Bioline Rx, Clever Leaves among healthcare movers